Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34324
Title: Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507).
Austin Authors: Tempo, Jake;Bolton, Damien M ;O'Callaghan, Michael
Affiliation: Austin Health
College of Medicine and Public Health, Flinders University, Adelaide, Australia.;Flinders Medical Centre, Urology Unit, Adelaide, Australia.;Discipline of Medicine, The University of Adelaide, Adelaide, Australia.
Issue Date: 24-Nov-2023
Date: 2023
Publication information: BMC Urology 2023-11-24; 23(1)
Abstract: The South West Oncology Group's 2000 randomised-control trial investigated the addition of maintenance intravesical bacillus Calmette-Guerin (BCG) to non-muscle invasive urothelial carcinoma (NMIUC) treatment. The results were published when the efficacy of BCG immunotherapy maintenance was unclear.Randomisation produced two arms, each containing 192 patients assessed to be at high risk of recurrence following induction BCG therapy for NMIUC. The treatment arm went on to receive three successive weekly intravesical and percutaneous BCG administrations at three months, six months and then six monthly for three years from the start of induction therapy.Recurrence free-survival (RFS), was higher in the maintenance arm with 41% (95%CI 35-49) RFS at five years in the control arm and 60% RFS (53-67 95% CI) in the maintenance arm (pā€‰<ā€‰0.0001). Only 16% of patients in the treatment arm received all of the scheduled maintenance courses of BCG.The study's seminal results correlate with contemporary systematic review and have guided international guidelines.
URI: https://ahro.austin.org.au/austinjspui/handle/1/34324
DOI: 10.1186/s12894-023-01352-0
ORCID: 
Journal: BMC Urology
Start page: 194
PubMed URL: 37996890
ISSN: 1471-2490
Type: Journal Article
Subjects: BCG
Bladder Cancer
Randomised Controlled Trial
Carcinoma, Transitional Cell/drug therapy
Carcinoma, Transitional Cell/pathology
Urinary Bladder Neoplasms/drug therapy
BCG Vaccine/therapeutic use
Urinary Bladder/pathology
Carcinoma in Situ/pathology
Carcinoma in Situ/therapy
Neoplasm Recurrence, Local/pathology
Adjuvants, Immunologic/therapeutic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

42
checked on Nov 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.